| Dr Dean Akira Inouye, MD | |
|
720 N Saint Asaph St, Alexandria, VA 22314-1912 | |
| (703) 746-3446 | |
| (703) 519-6521 |
| Full Name | Dr Dean Akira Inouye |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 38 Years |
| Location | 720 N Saint Asaph St, Alexandria, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902874605 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| City Of Alexandria | 0941195374 | 11 |
News Archive
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
For most people who contract it, dengue fever is a relatively mild-mannered disease-at least the first time around. For some, however, a subsequent infection by the virus unleashes a vicious and potentially deadly illness.
People with Type 2 diabetes who regained weight forfeited the initial benefits of reduced risk of heart disease or stroke compared to those who maintained their weight loss, according to new research published in the Journal of the American Heart Association, the open access journal of the American Heart Association.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
› Verified 2 days ago
| Entity Name | City Of Alexandria |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447279658 PECOS PAC ID: 0941195374 Enrollment ID: O20040216000939 |
News Archive
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
For most people who contract it, dengue fever is a relatively mild-mannered disease-at least the first time around. For some, however, a subsequent infection by the virus unleashes a vicious and potentially deadly illness.
People with Type 2 diabetes who regained weight forfeited the initial benefits of reduced risk of heart disease or stroke compared to those who maintained their weight loss, according to new research published in the Journal of the American Heart Association, the open access journal of the American Heart Association.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dean Akira Inouye, MD 720 N Saint Asaph St, Alexandria, VA 22314-1912 Ph: (703) 746-3446 | Dr Dean Akira Inouye, MD 720 N Saint Asaph St, Alexandria, VA 22314-1912 Ph: (703) 746-3446 |
News Archive
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].
For most people who contract it, dengue fever is a relatively mild-mannered disease-at least the first time around. For some, however, a subsequent infection by the virus unleashes a vicious and potentially deadly illness.
People with Type 2 diabetes who regained weight forfeited the initial benefits of reduced risk of heart disease or stroke compared to those who maintained their weight loss, according to new research published in the Journal of the American Heart Association, the open access journal of the American Heart Association.
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
› Verified 2 days ago
Dr. Nicholas Randall Morris, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2050 Ballenger Ave, Maia Institute, Alexandria, VA 22314 Phone: 301-500-0645 | |
Dr. Kevin Michael Williams, MD, MBA Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3737 Seminary Rd, Alexandria, VA 22304 Phone: 703-283-8679 Fax: 703-461-3448 | |
Dr. Rama Prayaga, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5194 Dawes Ave, Alexandria, VA 22311 Phone: 703-820-1900 Fax: 866-528-6229 | |
Dr. Israel M Labao Jr., M.D., M.P.H. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6910 Richmond Hwy Ste 110, Alexandria, VA 22306 Phone: 703-660-8100 Fax: 703-768-0103 | |
Dr. Simona Pick Both, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 8119 Holland Rd, Alexandria, VA 22306 Phone: 703-383-8500 | |
Dr. James Thomas Thornburgh, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 8119 Holland Rd, Alexandria, VA 22306 Phone: 703-799-2762 | |
Dr. Abdorasool Janati, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2863 Duke St, Alexandria, VA 22314 Phone: 703-801-7745 |